Project Grant R21AI190764
- Federal Grant Award Summary The University of Alabama at Birmingham received a $496,628 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 18, 2026, with completion targeted for January 31, 2031. This research project focuses on investigating the FC Receptor-Like (FCRL) gene family's mechanistic roles in B cell tolerance and malignancy, with particular emphasis on...
- Federal Project Grant Summary Award Overview Loyola University of Chicago's Health Sciences Campus received a $423,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 25, 2025, with a completion date of May 31, 2027. The research initiative focuses on developing novel antibodies targeting autoreactive B cells as a potential therapeutic intervention for systemic lupus...
- FEDERAL PROJECT GRANT AWARD SUMMARY The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Alabama at Birmingham a $632,423 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with a completion date of July 31, 2030. This research initiative focuses on elucidating the role of STAT4 (Signal Transducer and Activator of Transcription 4) in regulating pathogenic TH17 cell differentiation and...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $384,250 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 1, 2025, with completion targeted for April 30, 2027. This research project investigates PD-1/PD-L1 (Programmed Cell Death 1/Programmed Cell Death Ligand 1) signaling at the interface between immune and stem cell interactions, specifically...
- Federal Grant Award Summary The University of Oklahoma Health Sciences Center received a $1,049,245 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 4, 2025, with completion targeted for August 31, 2029. This grant supports biomedical research investigating the role of ARID3A (A+T-Rich Interaction Domain Protein 3A) in autoimmune B cell dysfunction associated with...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Alabama a $431,147 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year period from July 1, 2025, through June 30, 2027. The research project, titled "Innate Immune Regulation of Monoclonal Antibody-Induced Infusion Reactions," addresses the mechanisms underlying adverse immune reactions that occur during...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Alabama at Birmingham $587,885 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research defining the structure-function relationships of influenza virus non-structural proteins NS1 and nuclear export protein (NEP). The research project, initiated September 18, 2025, and scheduled for completion by August 31, 2030, will focus on...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $742,499 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 12, 2025, with completion targeted for July 31, 2030. This research grant supports a molecular investigation into siderophore secretion and drug efflux mechanisms in Mycobacterium tuberculosis (M. tuberculosis). The project will advance...
- Federal Project Grant Award Summary Biotherapeutics, Inc. received a $314,363 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025, through January 31, 2026. The award supports the development of a novel oral small molecule therapeutic candidate for treating systemic lupus erythematosus (SLE), an autoimmune disease affecting 1.5 million Americans. The company has...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded La Jolla Institute for Immunology a Project Grant of $476,436 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period February 5, 2026 through January 31, 2028. The award supports research to define the function and regulation of ILRUN, a novel Systemic Lupus Erythematosus (SLE)-susceptibility gene identified through genome-wide association studies as...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Alabama at Birmingham $409,750 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 9, 2026. This project grant funds research investigating the suppression of T-bet+ B cells in systemic lupus erythematosus (SLE) through tryptophan metabolites. The research aims to identify immunoregulatory metabolic signals induced by interleukin-4 (IL-4) that suppress toll-like receptor 7 (TLR7) stimulation of lupus pathogenic B cells, and to develop safer SLE therapeutics utilizing immune-regulatory metabolites to inhibit TLR7-induced lupus pathogenic B cell development. The primary deliverables include scientific research outcomes across two main aims: Aim 1 will determine the tryptophan metabolic signals induced by IL-4 to inhibit TLR7-induced lupus autoantibody precursor B cells in vivo, examining the induction and essential role of B-cell endogenous IL4I1, IDO1, and aryl hydrocarbon receptor (AHR) in wild-type and knockout mice models. Aim 2 will evaluate therapeutic efficacy of identified metabolites in suppressing lupus pathogenic B cell development. The project period extends through January 31, 2028, with research being conducted in Birmingham, Alabama.Federal Project Grant Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $409.8k | 2/9/26 |